ATAI Life Sciences BV (ATAI)vsMerck & Company Inc (MRK)
ATAI
ATAI Life Sciences BV
$7.35
0.00%
HEALTHCARE · Cap: $2.70B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 1488473% more annual revenue ($66.57B vs $4.47M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
ATAI
Avoid28
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+62.8%
Fair Value
$10.66
Current Price
$7.35
$3.31 discount
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 137.0% year-over-year
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Trading at 15.3x book value
0.0% margin — thin
ROE of -378.0% — below average capital efficiency
Earnings declined 96.8%
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : ATAI
The strongest argument for ATAI centers on Revenue Growth, Debt/Equity. Revenue growth of 137.0% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : ATAI
The primary concerns for ATAI are Price/Book, Profit Margin, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
ATAI profiles as a hypergrowth stock while MRK is a value play — different risk/reward profiles.
ATAI carries more volatility with a beta of 1.55 — expect wider price swings.
ATAI is growing revenue faster at 137.0% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (36/100 vs 28/100). ATAI offers better value entry with a 62.8% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
ATAI Life Sciences BV
HEALTHCARE · BIOTECHNOLOGY · USA
ATAI Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?